Literature DB >> 19579612

Allele frequency of thiopurine methyltransferase and inosine triphosphate pyrophosphatase gene polymorphisms in Korean patients with inflammatory bowel diseases.

Jae Hee Cheon1, Jae Hak Kim, Bo Young Kim, Seung Won Kim, Sung Yi Hong, Chang Soo Eun, Seong Soo Hong, Jeong-Sik Byeon, Tae Il Kim, Dong Soo Han, Suk-Kyun Yang, Kyoung Ryul Lee, Won Ho Kim.   

Abstract

BACKGROUND/AIMS: Adverse reactions to thiopurines may be predisposed by thiopurine methyltransferase (TPMT) or inosine triphosphate pyrophosphatase (ITPA) gene mutations.
METHODOLOGY: We examined the frequencies of TPMT and ITPA gene polymorphisms in 812 Korean patients with inflammatory bowel diseases using denaturing high performance liquid chromatography and direct sequencing.
RESULTS: The allele frequencies of TPMT*2, TPMT*3A, TPMT*3B, and TPMT*3C were 0, 0, 0, and 0.010 (17/1624), respectively. For the ITPA polymorphism, 173 subjects were heterozygous and 5 were homozygous for the 94C>A missense mutation (allele frequency of A, 0.113). Moreover, the 87T>C, IVS2+21A>C, and IVS2+53C>T polymorphisms were found in one patient each (1/1624), respectively. Of these, 87T>C and IVS2+53C>T were novel single nucleotide polymorphisms of the ITPA gene whose clinical significance should be further evaluated.
CONCLUSIONS: Our data describe TPMT and ITPA gene mutation patterns among Koreans and provide a basis for screening studies to identify patients at high risk for myelotoxicity from thiopurine drugs.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19579612

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  8 in total

1.  Inflammatory bowel disease in Korea: epidemiological, genomic, clinical, and therapeutic characteristics.

Authors:  Eun Soo Kim; Won Ho Kim
Journal:  Gut Liver       Date:  2010-03-25       Impact factor: 4.519

2.  Outcome predictors for thiopurine maintenance therapy in patients with Crohn's disease.

Authors:  Jae Jun Park; Jae Hee Cheon; Sung Pil Hong; Tae Il Kim; Won Ho Kim
Journal:  Dig Dis Sci       Date:  2011-11-06       Impact factor: 3.199

3.  Thiopurine-methyltransferase variants in inflammatory bowel disease: prevalence and toxicity in Brazilian patients.

Authors:  Ana Teresa P Carvalho; Barbara C Esberard; Renata S B Fróes; Davy C M Rapozo; Ana B Grinman; Tatiana A Simão; Juliana C V C Santos; Antonio José V Carneiro; Luis Felipe Ribeiro-Pinto; Heitor S P de Souza
Journal:  World J Gastroenterol       Date:  2014-03-28       Impact factor: 5.742

Review 4.  Thiopurine S-Methyltransferase as a Pharmacogenetic Biomarker: Significance of Testing and Review of Major Methods.

Authors:  Chingiz Asadov; Gunay Aliyeva; Kamala Mustafayeva
Journal:  Cardiovasc Hematol Agents Med Chem       Date:  2017-11-08

5.  Erythrocyte Inosine triphosphatase activity: A potential biomarker for adverse events during combination antiretroviral therapy for HIV.

Authors:  N Chantal Peltenburg; Jörgen Bierau; Jaap A Bakker; Jolanda A Schippers; Selwyn H Lowe; Aimée D C Paulussen; Bianca J C van den Bosch; Mathie P G Leers; Bettina E Hansen; Annelies Verbon
Journal:  PLoS One       Date:  2018-01-12       Impact factor: 3.240

6.  The Identification of a Novel Thiopurine S-Methyltransferase Allele, TPMT*45, in Korean Patient with Crohn's Disease.

Authors:  Changhee Ha; Eun Sil Kim; Yiyoung Kwon; Yon Ho Choe; Mi Jin Kim; Soo-Youn Lee
Journal:  Pharmgenomics Pers Med       Date:  2020-11-26

7.  APEX1 Polymorphism and Mercaptopurine-Related Early Onset Neutropenia in Pediatric Acute Lymphoblastic Leukemia.

Authors:  Hyery Kim; Heewon Seo; Yoomi Park; Byung-Joo Min; Myung-Eui Seo; Kyung Duk Park; Hee Young Shin; Ju Han Kim; Hyoung Jin Kang
Journal:  Cancer Res Treat       Date:  2017-09-04       Impact factor: 4.679

8.  The Effect of NUDT15, TPMT, APEX1, and ITPA Genetic Variations on Mercaptopurine Treatment of Pediatric Acute Lymphoblastic Leukemia.

Authors:  Jae Min Lee; Ye Jee Shim; Do-Hoon Kim; Nani Jung; Jung-Sook Ha
Journal:  Children (Basel)       Date:  2021-03-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.